Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 5Withdrawn 1Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 4Prostatic Neoplasms 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Sarcoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Meningeal Carcinomatosis 1Lymphoma 1Hodgkin Disease 1Head and Neck Neoplasms 1Brain Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Radiotherapy 9Cisplatin 9Paclitaxel 6Carboplatin 6Radiation 3Biopsy 3Bevacizumab 3balstilimab 2Topotecan 2Taxes 2Nivolumab 2Ipilimumab 2Gemcitabine 2Colposcopy 2Brachytherapy 2tislelizumab 1spartalizumab 1sitravatinib 1rucaparib 1pazopanib 1infigratinib 1fludarabine 1bemarituzumab 1atezolizumab 1aldesleukin 1Watchful Waiting 1Vinorelbine 1Vaginal Smears 1Ultrasonography 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Uterine Cervical Neoplasms × Vinorelbine × Clear all
NCT04943627 2022-10-05

Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)

Agenus Inc.

Phase 3 Withdrawn
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡